Design and evaluation of primaquine-artemisinin hybrids as a multistage antimalarial strategy

Antimicrobial Agents and Chemotherapy

Volumn 55, Issue 10, 2011, Pages 4698-4706

  Capela, Rita ^a   Cabal, Ghislain G ^b   Rosenthal, Philip J ^c   Gut, Jiri ^c   Mota, Maria M ^b   Moreira, Rui ^a   Lopes, Francisca ^a   Prudêncio, Miguel ^b  

^a RESEARCH INSTITUTE FOR MEDICINES IMED ULISBOA   (Portugal)

^b INSTITUTO DE MEDICINA MOLECULAR   (Portugal)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTELINIC ACID; ARTEMISININ; DIHYDROARTEMISININ; PRIMAQUINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIMALARIAL ACTIVITY; ARTICLE; BLOOD; CONTROLLED STUDY; DISEASE SEVERITY; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; DRUG SYNTHESIS; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; LIVER; MOUSE; NONHUMAN; PHARMACOPHORE; PLASMODIUM BERGHEI; PLASMODIUM BERGHEI INFECTION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; SURVIVAL RATE;

ANIMALS; ANTIMALARIALS; ARTEMISININS; CELL LINE; HUMANS; MALARIA; MICE; PARASITEMIA; PLASMODIUM BERGHEI; PLASMODIUM FALCIPARUM; PRIMAQUINE;

EID: 80052865308     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.05133-11     Document Type: Article

References (39)

1. Alonso, P. L., et al. 2011. A research agenda for malaria eradication: drugs. PLoS Med. 8:e1000402.
2. Aslanian, R., et al. 2003. Identification of a dual histamine H1/H3 receptor ligand based on the H1 antagonist chlorpheniramine. Bioorg. Med. Chem. Lett. 13:1959-1961.
3. Baird, J. K., and S. L. Hoffman. 2004. Primaquine therapy for malaria. Clin. Infect. Dis. 39:1336-1345.
4. Bell, A. 2005. Antimalarial drug synergism and antagonism: mechanistic and clinical significance. FEMS Microbiol. Lett. 253:171-184.
5. Capela, R., et al. 2009. Artemisinin-dipeptidyl vinyl sulfone hybrid molecules: design, synthesis and preliminary SAR for antiplasmodial activity and falcipain-2 inhibition. Bioorg. Med. Chem. Lett. 19:3229-3232.
6. Cena, C., et al. 2003. Antiinflammatory, gastrosparing, and antiplatelet properties of new NO-donor esters of aspirin. J. Med. Chem. 46:747-754.
7. Chattopadhyay, R., et al. 2010. Establishment of an in vitro assay for assessing the effects of drugs on the liver stages of Plasmodium vivax malaria. PLoS One 5:e14275.
8. Coteron, J. M., et al. 2010. Falcipain inhibitors: optimization studies of the 2-pyrimidinecarbonitrile lead series. J. Med. Chem. 53:6129-6152.
9. Dao, N. V., et al. 2007. Vivax malaria: preliminary observations following a shorter course of treatment with artesunate plus primaquine. Trans. R. Soc. Trop. Med. Hyg. 101:534-539.
10. Dell'Agli, M., et al. 2006. High antiplasmodial activity of novel plasmepsins I and II inhibitors. J. Med. Chem. 49:7440-7449.
11. Dembele, L., et al. 2011. Towards an in vitro model of Plasmodium hypnozoites suitable for drug discovery. PLoS One 6:e18162.
12. Galappaththy, G. N., A. A. Omari, and P. Tharyan. 24 January 2007. Primaquine for preventing relapses in people with Plasmodium vivax malaria. Cochrane Database Syst. Rev. 1:CD004389. doi:10.1002/14651858. CD004389.pub2.
13. Grellepois, F., P. Grellier, D. Bonnet-Delpon, and J. P. Begue. 2005. Design, synthesis and antimalarial activity of trifluoromethylartemisinin- mefloquine dual molecules. Chembiochem 6:648-652.
14. Hindley, S., et al. 2002. Mechanism-based design of parasite-targeted artemisinin derivatives: synthesis and antimalarial activity of new diamine containing analogues. J. Med. Chem. 45:1052-1063.
15. Lipinski, C. A., F. Lombardo, B. W. Dominy, and P. J. Feeney. 2001. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 46:3-26.
16. Lolli, M. L., et al. 2001. A new class of ibuprofen derivatives with reduced gastrotoxicity. J. Med. Chem. 44:3463-3468.
17. Navaratnam, V., et al. 2000. Pharmacokinetics of artemisinin-type compounds. Clin. Pharmacokinet. 39:255-270.
18. Nosten, F., and N. J. White. 2007. Artemisinin-based combination treatment of falciparum malaria. Am. J. Trop. Med. Hyg. 77:181-192.
19. Pamplona, A., et al. 2007. Heme oxygenase-1 and carbon monoxide suppress the pathogenesis of experimental cerebral malaria. Nat. Med. 13:703-710.
20. Perez, M., et al. 1998. Design and synthesis of new potent, silent 5-HT1A antagonists by covalent coupling of aminopropanol derivatives with selective serotonin reuptake inhibitors. Bioorg. Med. Chem. Lett. 8:3423-3428.
21. Peters, W. 1999. The evolution of tafenoquine - antimalarial for a new millennium? J. R. Soc. Med. 92:345-352.
22. Ploemen, I. H., et al. 2009. Visualisation and quantitative analysis of the rodent malaria liver stage by real time imaging. PLoS One 4:e7881.
23. Posner, G. H., et al. 2003. Orally active, antimalarial, anticancer, artemisinin-derived trioxane dimers with high stability and efficacy. J. Med. Chem. 46:1060-1065.
24. Posner, G. H., et al. 1999. Orally active, hydrolytically stable, semisynthetic, antimalarial trioxanes in the artemisinin family. J. Med. Chem. 42:300-304.
25. Price, R. N., et al. 2007. Vivax malaria: neglected and not benign. Am. J. Trop. Med. Hyg. 77:79-87.
26. Prudencio, M., C. D. Rodrigues, R. Ataide, and M. M. Mota. 2008. Dissecting in vitro host cell infection by Plasmodium sporozoites using flow cytometry. Cell. Microbiol. 10:218-224.
27. Prudencio, M., et al. 2008. Kinome-wide RNAi screen implicates at least 5 host hepatocyte kinases in Plasmodium sporozoite infection. PLoS Pathog. 4:e1000201.
28. Prudencio, M., A. Rodriguez, and M. M. Mota. 2006. The silent path to thousands of merozoites: the Plasmodium liver stage. Nat. Rev. Microbiol. 4:849-856.
29. Rodrigues, C. D., et al. 2008. Host scavenger receptor SR-BI plays a dual role in the establishment of malaria parasite liver infection. Cell Host Microbe 4:271-282.
30. Romeo, S., et al. 2004. Plasmepsin II inhibition and antiplasmodial activity of Primaquine-Statine 'double-drugs.' Bioorg. Med. Chem. Lett. 14:2931-2934.
31. Shekalaghe, S., et al. 2007. Primaquine clears submicroscopic Plasmodiumfalciparum gametocytes that persist after treatment with sulphadoxine-pyrimethamine and artesunate. PLoS One 2:e1023.
32. Shekalaghe, S. A., et al. 2010. In Tanzania, hemolysis after a single dose of primaquine coadministered with an artemisinin is not restricted to glucose-6-phosphate dehydrogenase-deficient (G6PD A) individuals. Antimicrob. Agents Chemother. 54:1762-1768.
33. Smithuis, F., et al. 2010. Effectiveness of five artemisinin combination regimens with or without primaquine in uncomplicated falciparum malaria: an open-label randomised trial. Lancet Infect. Dis. 10:673-681.
34. Vale, N., R. Moreira, and P. Gomes. 2009. Primaquine revisited six decades after its discovery. Eur. J. Med. Chem. 44:937-953.
35. Walsh, J. J., and A. Bell. 2009. Hybrid drugs for malaria. Curr. Pharm. Des. 15:2970-2985.
36. Walsh, J. J., D. Coughlan, N. Heneghan, C. Gaynor, and A. Bell. 2007. A novel artemisinin-quinine hybrid with potent antimalarial activity. Bioorg. Med. Chem. Lett. 17:3599-3602.
37. Wells, T. N., P. L. Alonso, and W. E. Gutteridge. 2009. New medicines to improve control and contribute to the eradication of malaria. Nat. Rev. Drug Discov. 8:879-891.
38. White, N. 1999. Antimalarial drug resistance and combination chemotherapy. Philos. Trans. R. Soc. Lond. B Biol. Sci. 354:739-749.
39. World Health Organization. 2010. World malaria report 2010. World Health Organization, Geneva, Switzerland. http://www.who.int/malaria/world -malaria-report-2010/en/index.html.